[2-(3,4-DIMETHOXY-PHENYL)-ETHYLAMINO]-2-[HYDROXY-(4-NITROPHENYL)-METHYL]-BUTYRIC ACID METHYL ESTER


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	RCISQOIOURZNPV-UHFFFAOYSA-N
Smiles	COC(=O)C(CNCCc1ccc(OC)c(OC)c1)C(O)c2ccc(cc2)[N+](=O)[O-]
InChI	InChI=1S/C21H26N2O7/c1-28-18-9-4-14(12-19(18)29-2)10-11-22-13-17(21(25)30-3)20(24)15-5-7-16(8-6-15)23(26)27/h4-9,12,17,20,22,24H,10-11,13H2,1-3H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C21H26N2O7
Molecular Weight	418.44
AlogP	2.49
Hydrogen Bond Acceptor	8.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	12.0
Polar Surface Area	122.84
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	30.0

Assay Description	Organism	Bioactivity
Inhibition of P-glycoprotein in Homo sapiens (human) MCF7/ADR cells assessed as doxorubicin-induced growth inhibition after 48 hr by SRB assay (Doxorubicin Rvb = 5.1 +/-1.2%)	Homo sapiens	12.9 %
Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell proliferation after 48 hr by SRB assay	Homo sapiens	None
Cytotoxicity against Homo sapiens (human) MCF7/ADR cells assessed as inhibition of cell proliferation after 48 hr by SRB assay	Homo sapiens	85100.0 nM	Cytotoxicity against Homo sapiens (human) MCF7/ADR cells assessed as inhibition of cell proliferation after 48 hr by SRB assay	Homo sapiens	15.7 umol/L

Cross References

Resources	Reference
ChEMBL	CHEMBL2298613
PubChem	76331446

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).